Author:
Gidwani Beena,Gupta Sanjay Kumar,Sahu Jyoti
Abstract
Cancer is one of the most fatal and complicated diseases. Chemotherapeutic drugs occupy a crucial position in cancer treatment, although it is still challenging to cure it from the root cause without harming healthy cells. Adjuvant or neoadjuvant and concurrent chemotherapies are usually used along with surgery and radiotherapy, depending on the spreading of tumour cells to its vicinity. However, it cannot wholly kill cancerous cells, which further develop after a while; the reason behind this is poor drug pharmacokinetic and biopharmaceutical parameters. Considering the approach of calixarenes, it has significantly drawn attention that can lodge drug molecules by forming inclusion complexes due to their prominent geometrical shape distinguishing them from other heterocyclic compounds.
Moreover, it can be more beneficial if used with nano carrier-based systems like liposomes, liposomes, nanoparticles, micelles, milliards, and siRNA to deliver anticytotoxic agents. This review highlights the potential of calixarenes properties and nanocarrier calixarene-complexed based molecules, which provide better therapeutic properties without harming healthy cells due to their unique targeted attribution. Thus, it can overcome the problem arising from conventional therapies.
Publisher
BSP Books Private Limited
Subject
Pharmacology (medical),Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,Pharmacy
Reference72 articles.
1. K. D. Tripathi. Essentials of medical pharma-cology: jaypee brothers medical. 2018; 8th edition: 819
2. M. Yasir, M. Asif, A. Kumar, and A. Aggarval. Biopharmaceutical classification system an account. International journal of pharmtech research. 2010; 3[2]:1681–1690.
3. Vyas SP., Khar R.K. Basis of targeted drug delivery. In targeted and controlled drug delivery. C.B.S. publishers and distributors reprint 2008; 74: 42-46.
4. Stuurman FE., Nuijen B., Beijnenjh et al. Oral anticancer drugs mechanisms of low bioavailability and strategies for improvement. Clinical pharmacokinetics. 2013; 52[6]: 399-414.
5. Iqbal J., Anwar F., Afridi S. Targeted drug delivery systems and their therapeutic applications in cancer and immune pathological conditions. Infection Disorder. Drug targets. 2017; 17: 149–159.